PLoS ONE (Jan 2013)

Prognostic role of microRNA-181a/b in hematological malignancies: a meta-analysis.

  • Shenglong Lin,
  • Lili Pan,
  • Shicheng Guo,
  • Junjie Wu,
  • Li Jin,
  • Jiu-Cun Wang,
  • Shaoyuan Wang

DOI
https://doi.org/10.1371/journal.pone.0059532
Journal volume & issue
Vol. 8, no. 3
p. e59532

Abstract

Read online

BackgroundEmerging evidence has shown that miRNAs participate in human carcinogenesis as tumor suppressors or oncogenes, and have prognostic value for patients with cancers. In recent years, the miR-181 family was found dysregulated in a variety of human cancers and significantly associated with clinical outcome of cancerous patients. MiR-181a and miR-181b (miR-181a/b) were the most investigated members in the family. However, the results of miR-181a/b from different studies were inconsistent. Therefore, we performed a meta-analysis to summarize all the results from available studies, aiming to delineate the prognostic role of miR-181a/b in human cancers.MethodsThe identified articles were retrieved from the two main on-line databases, PubMed and EMBASE. We extracted and estimated the hazard ratios (HRs) for overall survival (OS), which compared the high and low expression levels of miR-181a/b in patients of the available studies. Each individual HR was used to calculate the pooled HR.ResultsEleven studies of 1252 patients were selected into the final meta-analysis after a strict filtering and qualifying process. Fixed model or random model method was chosen depending on the heterogeneity between the studies. The subgroup analysis showed that high expressed miR-181a/b could prolong OS in patients with hematological malignancies rather than low expression level (HR = 0.717, PConclusionOur study indicates that the expression level of miR-181a/b is significantly associated with OS in hematological malignancies and can be an important clinical prognostic factor for those patients.